durobinet schreef op 10 mei 2018 21:15:
Zoiets kan ook Galapagos gebeuren. Ik zeg kán, niet gaat gebeuren.
Inmiddels al ruim 13% down!
Why Exelixis Dropped Today
The company announced a disappointing clinical trial failure, which fortunately wasn't for its top-selling drug.
What happened
Shares of Exelixis (NASDAQ:EXEL) are down 12% at 2:02 p.m. EDT after announcing the IMblaze370 phase 3 trial testing its Cotellic with Roche's Tecentriq failed to improve overall survival compared to Bayer's Stivarga in patients with locally advanced or metastatic colorectal cancer.
www.fool.com/investing/2018/05/10/why...